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Abstract
Background: There is considerable interest in the impact of increased flavan-3-ol intake on cardiovascular disease
(CVD) and diabetes outcomes. Through evidence mapping, we determined the extent of the evidence base to
initiate a future systematic review investigating the impact of flavan-3-ol intake on CVD and diabetes outcomes.
Methods: We developed a research protocol, convened a technical expert panel (TEP) to refine the specific
research questions, conducted a systematic search in multiple databases, double-screened abstracts and full-text
articles, performed data extractions, and synthesized the data. We focused on randomized controlled trials (RCTs)
and prospective cohort studies which assessed intakes of flavan-3-ol from foods, beverages, and supplement/extract
sources on biomarkers and clinical outcomes of CVD and diabetes.
Results: Of 257 eligible articles, 223 and 34 publications contributed to 226 RCTs and 39 prospective cohort studies,
respectively. In RCTs, the most frequently studied interventions were cocoa-based products (23.2%); berries (16.1%); tea
in the form of green tea (13.9%), black tea (7.2%), or unspecified tea (3.6%); and red wine (11.2%). Mean total flavan-3-ol
intake was highest in the cocoa-based trials (618.7 mg/day) and lowest in the interventions feeding red wine (123.
7 mg/day). The most frequently reported outcomes were intermediate biomarkers including serum lipid levels (63.4%),
blood glucose (50.9%), blood pressure (50.8%), flow-mediated dilation (21.9%), and high-sensitivity C-reactive protein
(21.9%). The included 34 prospective cohort studies predominantly examined exposures to flavan-3-ols (26%),
cocoa-based products (23.2%), berries (16.1%), and green tea (13.9%) and CVD incidence and mortality.
Conclusion: Through a systematic, evidence-based approach, evidence mapping on flavan-3-ol intake and CVD
outcomes demonstrated sufficient data relating to flavan-3ol intake and biomarkers and clinical outcomes of CVD and
diabetes. The current evidence base highlights the distribution of available data which both support the development
of a future systematic review and identified the research need for future long-term RCTs.
Systematic review registration: At present, evidence mapping is not eligible for registration on the international
prospective register of systematic reviews (i.e., PROSPERO).
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Background
Dietary flavonoids represent a diverse range of polyphenolic
compounds that occur naturally in plant foods. Their struc-
tural complexity has led to their sub-classification as flavo-
nols, flavones, flavanones, flavan-3-ols (and their oligomers,
pro(antho)cyanidins), isoflavones, and anthocyanins [1]. Al-
though interest in the relationship between these bioactive
constituents and cardiovascular disease (CVD) and diabetes
risk is growing, their specific contribution to any health
effects and the underlying mechanisms by which they act is
an area of active research [2, 3].
To date, the sub-class that has received the most
attention is flavan-3-ols, although most of the studies to
date focus on two of the dietary sources, tea and choc-
olate. A number of meta-analyses have been published
on the existing population-based evidence for these indi-
vidual foods [1, 4–8]. Additionally, it is important to
note that any health benefit from intake of tea or choc-
olate may be attributed to other bioactive constituents
beyond flavan-3-ols and flavonoids, including other
phenolics, caffeine, theobromine [9–11]. To date, in ran-
domized controlled trials (RCTs) and prospective stud-
ies, although available findings on flavan-3-ols-rich foods
are promising, dose-responses varied and the overall re-
sults are mixed. Potential adverse effects of flavan-3-ol
extracts and supplements are also reported in literature
[12, 13]. Studying a broad range of food sources rich in
flavan-3-ols will help to further elucidate the potential
health effects of flavan-3-ols per se to improve cardio-
metabolic health.
Evidence mapping is a tool used to systematically iden-
tify, organize, and summarize the quantity and focus of
scientific evidence on a broad range of topics. Through
evidence mapping, we determine the extent of the evi-
dence base examining the impact of flavan-3-ol intake
on CVD and diabetes outcomes and associated risk fac-
tors in RCTs and prospective cohort studies. The overall
goal was to provide recommendations for future re-
search and to identify if there is sufficient evidence to
date to support initiating a full systematic review.
Methods
Description of evidence mapping
Evidence mapping is a tool to identify well-researched
areas as well as gaps in evidence. It is often conducted
to evaluate evidence on a broad topic before embarking
on a full systematic review [14, 15]. Evidence mapping
describes the characteristics of eligible literature typically
in tabular forms and figures. Creating an evidence map
usually involves the following steps: identifying a broad
research area, defining key questions and variables and
formulating a framework, engaging key stakeholders,
conducting a systematic literature search, selecting stud-
ies for inclusion according to a priori eligibility criteria,
and reporting descriptive results in tabular formats. In
contrast to conducting a systematic review, evidence
mapping does not necessitate detailed extraction, the
assessment of risk of bias, and quantitative synthesis of
results from eligible studies.
Scope of the evidence map
Currently, there is no prescribed methodological or
reporting standard (i.e., for evidence mapping) and,
therefore, we followed a series of logical steps in creating
this evidence map. First, we assembled a review team
and developed a protocol; identified and convened a
technical expert panel (TEP) with content expertise,
methodological expertise, or both; refined specific re-
search questions with the input of the TEP; and con-
ducted a systematic search in multiple databases. We
then double-screened abstracts and full-text articles, per-
formed data extractions, and synthesized data in tabular
forms. The data was used to identify areas within the
topic of flavan-3-ols and cardiovascular outcomes with a
paucity of research that are ideal focuses for future studies,
as well as well-researched topics where there is sufficient
evidence to warrant a full systematic review.
Review team and development of a protocol
Our review team was comprised of two nutrition re-
searchers with expertise in flavan-3-ols, one methodologist,
and three research assistants with an interest and training in
nutrition research. First, we identified preliminary key ques-
tions and study eligibility criteria through discussions of
Populations, Interventions/Exposures, Comparators, Out-
comes, and Study designs or Settings (PI(E)COS) of interest
and developed the analytic framework (Fig. 1). Next, we uti-
lized the United States Department of Agriculture (USDA)
monomer and procyanidin databases or Phenol-Explorer
databases to identify commonly consumed foods and bever-
ages that have the highest flavan-3-ol content—either as
monomers or polymers—and assembled a comprehensive
list of them in an Excel™ spreadsheet [16–18]. We did not
search for foods that have low flavan-3-ol content but are
consumed at a high frequency. A detailed search strategy
and protocol was then developed outlining key questions
and the scope of the review. This review was submitted to
the International Life Sciences Institute (ILSI) bioactive
committee for their input, but we retained the independence
to decide whether or not to incorporate any suggestions re-
ceived from the committee.
Technical expert panel
Our review team identified and convened a multidisciplinary
TEP, which included four flavan-3-ol researchers from the
USDA, academic centers in North America and the UK;
two methodologists with expertise in nutrition research; and
a cardiologist. The TEP provided input to help refine the
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questions and protocol, identify important issues, and define
parameters for the mapping of evidence. The review team
also asked the TEP to suggest additional search strategy
terms. See Additional file 1: Table S1 for a list of TEP mem-
bers and affiliations.
Search strategy
A comprehensive search of the scientific literature was
conducted in MEDLINE®, the Cochrane Central Trials
Registry®, and Commonwealth Agricultural Bureau
(CAB) from inception through April 26, 2016. The refer-
ence lists of any previously published systematic reviews
on flavonoids and health identified by the review team
or TEP were hand-searched to identify any additional
studies not captured by the database searches.
To capture interventions of interest, we combined terms
of monomer and proanthocyanidins for flavan-3-ols, foods,
beverages, and spices (e.g., cinnamon) rich in flavan-3-ols
with the outcomes of interest including any cardiovascular
outcomes and intermediate biomarkers, inflammatory
markers, and endothelial function. The search strategy in-
cluded terms for the study designs of interest (i.e., random-
ized trials and prospective cohort studies) and was limited to
those conducted in humans (see Additional file 1: Table S2
for the complete search strategy). No language restriction
was applied during the search process.
Study selection
Our review team used an iterative process to establish
study eligibility criteria based on the aforementioned
PI(E)COS, detailed in Tables 1 and 2. Using these cri-
teria, we assessed abstracts and/or titles of citations
identified from literature searches for inclusion, retrieved
full-text articles of potentially relevant citations, and
re-assessed the articles for inclusion. Articles published
in the English language were selected. Both abstract and
full-text screenings were conducted in duplicate, with
conflicts resolved by reconciliation with the whole
research team in weekly group meetings. The project
lead reconfirmed all rejected full-text articles. Addition-
ally, content experts were consulted through emails for
questions that arose in weekly group meetings.
Data extraction
In discussion with nutrition experts within the review
team, data was extracted into customized forms in the
Systematic Review Data Repository (SRDR) online sys-
tem (https://srdr.ahrq.gov). The forms were designed to
capture all elements relevant to the descriptions on
study population characteristics, enrolled and analyzed
sample sizes, study design features, interventions and
comparators, and relevant outcomes. If flavan-3-ol levels
were not explicitly reported in the paper, where possible,
data extractors estimated flavan-3-ol intake levels using
either the USDA monomer and proanthocyanidins or
Phenol-Explorer databases [16–18]. We also extracted
qualitative outcomes (i.e., direction of association and
statistical significance). The forms were piloted on
several studies, revised, and optimized as necessary by the
project lead. One team member extracted each study’s
data. A second team member confirmed interventions
and outcome data entries at the time of data analysis.
Data synthesis
All included studies were summarized in narrative form
and in summary tables that tabulated the important
Fig. 1 Analytic framework for evaluating the association between flavan-3-ol and outcomes. Legend: Analytic framework displays the potential
association pathway between flavan-3-ol and outcomes of interest
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features of the study populations, designs, interventions,
outcomes, and results. Studies were also summarized quali-
tatively in tabular form and graphically using heat maps.
Results
We identified 3194 abstracts examining flavan-3-ol intakes
and cardiovascular outcomes (including MI, stroke) and a
range of CVD risk factors. Of these, 536 (16.8%) abstracts
met the broad eligibility criteria and were retrieved and
re-examined as full-text articles; 257 of the full-text articles
(223 RCTs and 34 prospective studies) were eligible for data
entry into the final database (Fig. 2). Of the 257 articles,
223 publications contributed to 226 RCTs and 34 publica-
tions contributed to 39 prospective observational cohort
studies (i.e., some articles reported multiple studies), and
eligible studies are listed in the Additional file 1.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Populations: humans only Populations: those including:
Adults 18+ years of age Non-human subjects (e.g., in vitro, cell, stem cell, or animal studies)
Healthy adults
Adults at an increased risk for cardiovascular disease (CVD) Children and adolescents (< 18 years old)
Adults who had existing CVD Pregnant or lactating women
Cancer survivors who were cancer-free at the time of the study Adults with prior organ transplantation
All elderly unless clear disease (e.g., renal disease) Adults with chronic, inflammatory, or autoimmune disease conditions
(e.g., rheumatoid arthritis, polycystic ovarian syndrome,
chronic kidney disease)
100% smokers
Participants in concurrent cancer or exercise trials
Studies with < 10 subjects
Interventions: Interventions:
Foods, beverages, supplements, or extracts that described or defined
flavan-3-ol content either as monomers or polymers
Did not evaluate a specific intervention
(e.g., spice blend, dietary patterns rich in flavan-3-ol food sources)
Foods with no or low flavan-3-ol content
(e.g., white chocolate, raisins)
Example foods: fruits (e.g., apples, berries, grapes), dark chocolate,
cocoa, teas, red wine)
Foods with insufficient data to allow a reasonable estimation
of flavan-3-ol content using standardized databases [16–18]
Studies must quantify flavan-3-ols consumed or provide sufficient data
that allowed estimation of the flavan-3-ol content via standardized
databases1 [16–18]
Did not specify the type of wine (e.g., white, red, rice), alcohol,
or chocolate (e.g., dark, white, or milk chocolate) in their
questionnaires and/or reported results
Comparators of interest: Comparators of interest:
Low or no flavan-3-ol content, including placebos Studies that did not differentiate flavan-3-ol content
(e.g., a study evaluating the effects of alcohol comparing
red wine vs. de-alcoholized red wine)
Outcomes of interest: Outcomes of interest:
Key clinical and intermediate outcomes (Table 2)2 Clinical and intermediate outcomes of interest (Table 2) that do
not meet the minimum follow-up requirements
Study designs of interest: Study designs of interest:
Randomized controlled trials (RCTs) Cross-sectional studies
Prospective cohort studies Case reports
Case series
Retrospective studies
Systematic reviews and meta-analyses3
Reviews, lectures, opinion articles, news articles, proposed studies
(i.e., no results reported)
1For all interventions of interest when flavan-3-ols were not fully reported in an article, we utilized the recent USDA monomer and procyanidin databases or
Phenol-Explorer databases to estimate flavan-3-ol content–either as monomers or procyanidin based on the intake values reported in each article.
2When outcomes were reported at multiple time points, only baseline and final follow-up results were extracted
3Though systematic reviews and meta-analyses were excluded during the screening process, their references were screened for any additional, relevant studies
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Description of RCTs
The 223 articles were published between March 1985 and
April 2016 and contributed to 226 RCTs in the database
(i.e., three publications contained two RCTs each) (Fig. 3).
The top three regions where the RCTs were conducted
were Western Europe (38.6%), North America (26.5%),
and Asia (13.0%). The majority of RCTs were parallel
study designs (62.3%), and the remaining were (37.7%)
crossover studies. Regarding blinding, 55.6% of the RCTs
were double-blinded, 17.9% were single-blinded, 11.2%
were not blinded, and 15.3% did not explicitly report on
blinding. Over half of the RCTs were conducted among
adults ≥ 50 years of age (56.1%); 57.0% included predom-
inantly metabolically at-risk adults; 29.2% included healthy
adults (i.e., adults without any risk factors for CVD or
without existing CVD); 4.9% included adults with existing
CVD; 4.9% included adults with more than one of the
Table 2 Included outcomes of interest and minimum
follow-up cutoffs
○ Cardiovascular disease (CVD) clinical outcomes (≥ 6 months follow-up),
including acute coronary syndrome, angina, arteriosclerosis, atherosclerosis,
atrial fibrillation, cerebrovascular disorders, coronary artery disease, heart
failure, myocardial infarction, peripheral vascular disease, and venous
thromboembolism1
○ Serum lipids (≥ 3 weeks follow-up),including blood pressure (BP),
diastolic BP (DBP), low-density lipoprotein (LDL), high-density
lipoprotein (HDL), systolic BP (SBP), total cholesterol, triglycerides
○ Inflammatory markers (≥ 3 weeks follow-up), including high-sensitivity
C-reactive protein (hs-CRP), intercellular adhesion molecule 1 (ICAM-1),
interleukins, vascular cell adhesion molecule 1 (VCAM-1)
○ Metabolic parameters (≥ 1 week follow-up), including blood glucose,
diabetes, hemoglobin A1C (HbA1C), homeostatic model assessment
and insulin resistance (HOMA-IR), insulin resistance, quantitative insulin
sensitivity check index (QUICKI)
○ Evaluation of endothelial function (any study length, including
acute studies), using Endo-PAT, flow-mediated dilation (FMD),
pulse-amplitude, pulse wave analysis, pulse wave velocity
1When outcomes were reported at multiple time points, the results reported
at baseline and the final follow-up were extracted
Fig. 2 Study Flow Diagram. Legend: Abstracts identified (n = 3194); Abstracts not meeting criteria (n = 2658); Full-text articles excluded after
screening (n = 279); Full-text articles meeting study eligibility criteria (n = 257); Eligible randomized controlled trials (n = 223) and prospective
observational studies (n = 34). RCTs = randomized controlled trials
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aforementioned categories; and 4.0% included adults with
other conditions at baseline.
Included interventions of interest
The most frequently studied intervention in RCTs was
cocoa-based products (23.2%), consumed as dark choc-
olate, cocoa, or added cocoa polyphenols. The second
most frequently studied intervention was tea in the form
of green tea (13.9%), black tea (7.2%), or unspecified tea
(3.6%), followed by berries and red wine in 16.1 and
11.2% of the RCTs, respectively. Less than 10% of the
RCTs included other interventions such as apples, cinna-
mon, cranberries, flavan-3-ol monomer or proanthocya-
nidin supplementation, grapes, grape seed, plums, and
mixed interventions of interest. Table 3 illustrates the
evaluation of these interventions.
Mean total flavan-3-ol intake varied across interven-
tions. It was highest for RCTs administering chocolate
(618.7 mg/day), green tea (473.4 mg/day) or black tea
(256.2 mg/day), apples (444.1 mg/day), flavan-3-ol mono-
mers (350.7 mg/day), berries (250 mg/day), and red wine
(123.7 mg/day). Across interventions, the average study
duration ranged between 4 and 17 weeks. A detailed de-
scription of reported or estimated flavan-3-ols is tabulated
in the Additional file 1.
Outcomes of interest
The most frequently reported outcomes in RCTs of berries,
cocoa-based products, green tea, and wine were blood
glucose (50.9%), blood pressure (BP) (50.8%), serum lipid
levels (63.4%), flow-mediated dilation (FMD) (21.9%), and
high-sensitivity C-reactive protein (hs-CRP) (21.9%) (Figs. 4
and 5). In addition, cinnamon trials frequently reported
blood glucose and blood lipid outcomes, grape seed trials re-
ported FMD and hs-CRP, and cranberry trials reported
hs-CRP. The sample sizes per trial ranged from 42 to 70
subjects. Though trials overall were more likely to report
improvements in evaluated outcomes after the intervention
as compared with the control (Additional file 1), within each
group (compared to baseline) statistical significance was
reached in < 50% of the studies and between groups
(intervention vs. control) statistical significance was
reached in < 25% of the studies.
Descriptive data on additional outcomes included insulin
resistance or homeostatic model assessment and insulin re-
sistance (HOMA-IR) (18.9%), oxidized low-density lipopro-
tein (LDL) (12.1%), pulse-wave velocity (14.3%), intercellular
adhesion molecule 1 (ICAM-1) (11.6%), vascular cell adhe-
sion molecule 1 (VCAM-1) (12.1%), interleukin-6 (12.9%),
tumor necrosis factor alpha (TNF-alpha) (11.2%), and other
outcomes (< 10%).
Description of cohort studies
The 39 prospective cohort studies (in 34 publications)
represented 47 adjusted models. The cohort studies were
conducted in Europe (16 studies), the USA (10 studies),
Asia (7 studies), and Australia (1 study). The exposures
examined included total dietary flavan-3-ol intake (9
Fig. 3 Bar graph displaying the mean number of RCT and observational study flavan-3-ols articles published per year between 1985 and 2016.
RCT = randomized controlled trial
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models; 37,382 subjects); berries (6 models; 54,780
subjects); apples (5 models; 53,383 subjects); green tea (5
models; 25,420 subjects); cocoa-based products (4
models; 27,028 subjects); black tea (3 models; 42,699
subjects); monomer intake (3 models; 24,746 subjects);
grape and raisins (3 models; 62,461 subjects); plums (3
models; 27,365 subjects); red wine (3 models; 5434 sub-
jects); unspecified type of tea (2 models; 5399 subjects);
Table 3 Descriptive characteristics of eligible RCTs
Total N (%) RCT parallel N (%) RCT crossover N (%)
N publications 223 (100.00) 139 (62.33) 84 (37.67)
Blinding
Double-blind 124 (55.61) 87 (62.59) 37 (44.05)
Single-blind 40 (17.94) 19 (13.67) 21 (25.00)
Not blinded 25 (11.21) 14 (10.07) 11 (13.10)
Not reported 34 (15.25) 19 (13.67) 15 (17.86)
Mean age
< 50 years 98 (43.95) 57 (41.01) 41 (48.81)
≥ 50 years 125 (56.05) 82 (58.99) 43 (51.19)
Baseline health
Healthy 65 (29.15) 29 (20.86) 36 (42.86)
At risk for CVD 127 (56.95) 91 (65.47) 36 (42.86)
Existing CVD 11 (4.93) 5 (3.60) 6 (7.14)
Mixed 11 (4.93) 6 (4.32) 5 (5.95)
Other 9 (4.04) 8 (5.76) 1 (1.19)
Study region
Africa 2 (0.90) 0 (0.00) 2 (2.38)
Asia 29 (13.00) 28 (20.14) 1 (1.19)
Australia 12 (5.38) 6 (4.32) 6 (7.14)
Eastern Europe 5 (2.24) 5 (3.60) 0 (0.00)
Western Europe 86 (38.57) 38 (27.34) 48 (57.14)
Middle East 24 (10.76) 23 (16.55) 1 (1.19)
North America 59 (26.46) 34 (24.46) 25 (29.76)
South America 5 (2.24) 4 (2.88) 1 (1.19)
Mixed 1 (0.45) 1 (0.72) 0 (0.00)
Intervention
Apple 4 (1.79) 1 (0.72) 3 (3.57)
Berries 36 (16.14) 24 (17.27) 12 (14.29)
Black tea 16 (7.17) 9 (6.47) 7 (8.33)
Chocolate 52 (23.21) 27 (19.42) 25 (29.76)
Cinnamon 18 (8.07) 17 (12.23) 1 (1.19)
monomers 9 (4.04) 6 (4.32) 3 (3.57)
polymers 1 (0.45) 1 (0.72) 0 (0.00)
Grape 7 (3.14) 4 (2.88) 3 (3.57)
Grape seed 13 (5.83) 9 (6.47) 4 (4.57)
Green tea 31 (13.90) 26 (18.71) 5 (5.95)
Mixed/other 3 (1.35) 3 (2.16) 0 (0.00)
Tea 8 (3.59) 4 (2.88) 4 (4.76)
Wine 25 (11.21) 8 (5.76) 17 (20.24)
CVD cardiovascular disease, N number, RCT randomized controlled trial
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and proanthocyanidin intake (1 model; 40,574 subjects).
Across cohort studies, the average study duration ranged
between 4.5 and 24 years. The associated cardiovascular
outcomes examined included cardiovascular mortality,
cerebrovascular stroke, and BP.
Discussion
This evidence mapping on flavan-3-ol intakes identified
that cocoa-based products, tea, berries, and red wine
each have several published RCTs examining relevant
CVD and diabetes outcomes of interest. Additionally,
Fig. 4 Heat map showing the distribution of RCTs by their intervention arms and most commonly evaluated outcomes. RCTs = randomized controlled trials
Fig. 5 Heat map showing the distribution of RCTs by their intervention arms and less frequently evaluated outcomes. RCTs = randomized controlled trials
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aside from an overall focus on total flavan-3-ol intake,
berries, apples, green tea, and cocoa-based products
were the predominant, habitual dietary sources.
Description of existing literature
A number of meta-analyses have been published on the
existing population-based evidence for some of these
foods individually, but none has been conducted evaluat-
ing a broad range of topics with a specific focus toward
total flavan-3-ol intake [4, 6]. A previous systematic re-
view on chocolate, which included six cohort studies and
one cross-sectional study, showed that higher intake was
associated with a 37% (95% CI 10–46%) reduction in risk
for CVD and 29% (2–48%) reduction in risk for stroke,
compared with lower intake [4]. Largely based on the same
studies, three other meta-analyses of population-based data
reported relative risk (RR) reductions of between 13 and
25% for stroke [6] in the highest (median 62.9 g/week)
versus the lowest (0 g/week) intake of chocolate. For tea, a
recent meta-analysis of 22 prospective studies reported that
a 3 cup/day increase in consumption was associated with a
reduction in risk of incident heart disease (RR, 0.73; 95% CI
0.53–0.99), incident stroke (RR, 0.82; 95% CI 0.73–0.92),
and total mortality (RR, 0.76; 95% CI 0.63–0.91), but
had no significant effect on stroke mortality (RR, 0.93;
95% CI 0.83–1.05) [8].
Three meta-analyses of RCTs [7, 19, 20] that reviewed
the impact of cocoa/chocolate consumption on cardio-
metabolic health from the available short duration
(≤ 18 weeks) studies reported similar effects, despite
minor differences in inclusion criteria in two RCTs
[7, 19]. One meta-analysis reported a − 2.77 mmHg
(95% CI − 4.72, − 0.82 mmHg, p = 0.005) decrease in sys-
tolic BP and − 2.20 mmHg (95% CI − 3.46, − 0.93 mmHg,
p = 0.006) reduction in diastolic BP following cocoa intake
(17). The other systematic reviews, which had minor
differences in inclusion criteria, reported similar effects
[7, 19]. The magnitude of associations are clinically
relevant and of significant public health importance.
For tea, one meta-analysis of 11 short-term RCTs
(duration 1–26 weeks) observed reductions in systolic
BP and diastolic BP [5], while another meta-analysis of
10 studies suggested that consumption of black tea sig-
nificantly reduced LDL cholesterol concentrations but
did not alter total or high density lipoprotein (HDL)
cholesterol levels [21].
In relation to the specific associations between habitual in-
takes of flavan-3-ols and CVD, the most recent review of
prospective cohort studies reported no association with cor-
onary heart disease (CHD) mortality, CHD incidence, and
stroke risk [22]. However, in one study, higher flavan-3-ol
intake (monomers only) was associated with a 17% decrease
in CVD mortality [23]. Two other studies, which included
both monomers and other pro(antho)cyanidins, also
reported a 66% decrease in atherosclerotic vascular disease
mortality [24] and a 60% decrease in CVD events and mor-
tality [25]. In relation to procyanidin intake alone, a higher
intake was associated with a 10–13% decrease in CVD mor-
tality in two studies [23, 26] and a 17% decrease in incident
and fatal CHD in one study [27].
In relation to RCTs, to date, three systematic reviews
have examined the potential effective dose of flavan-3-ols
from the short-term trials on tea and cocoa. One observed
a non-linear dose-response effect with a maximal effect
observed at a “total polyphenol intake” of 500 mg [7].
Another suggested that intakes of epicatechin > 50 mg
resulted in greater effects on systolic BP and diastolic BP,
while FMD improved at all levels of epicatechin intake [1].
The most recent systematic review suggested that the acute
and chronic FMD and BP responses for epicatechin,
catechin, or procyanidin intakes were marginally greater
for these individual constituents compared to total
flavan-3-ol intake [28]. Furthermore, while there was no
indication of a dose-response for BP, there were non-linear
dose-response relationships observed for FMD, with a
greater acute response observed at lower intake levels
(< 1 g/day procyanidins, < 200 mg/day monomers) and a
U-shaped response observed following chronic ingestion
[28]. Several flavan-3-ol studies have also been conducted
focusing on feeding chemically “pure” (-) – epicatechin to
participants. Two recent studies administered 100 mg/day
of epicatechin to participants for 4 weeks. One reported no
change in FMD or BP but did report improvements in
insulin resistance [29], while the second also reported
favorable effects on insulin resistance and improvements in
both inflammatory and lipid biomarkers [30].
Role and value of evidence mapping
There is an increasing interest in these types of evidence
mapping methods to create databases for identification
of gaps or topics for future reviews [31, 32]. At the out-
set, we identified two experts from the flavan-3-ol re-
search community and consulted with them throughout
the review process. These experts assisted with the pre-
liminary refinement of the PI(E)COS definitions, the
analytic framework, and the review of evidence mapping
results, and confirmed that the evidence mapping was
thorough and comprehensive.
Prior to the review of abstracts and full-text articles, the
review team received training on the screening process
about how to identify relevant abstracts and articles using
the pre-specified eligibility criteria. Key steps of this evi-
dence mapping included (1) the determination of appro-
priate clinical and biochemical markers as outcomes of
interest; (2) the use of appropriate duration of follow-up
to assess each of the outcomes; (3) the review of abstracts
and full-text articles for relevance from a broad range of
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topics; (4) the estimation of the flavan-3-ol content from
relevant databases when they were not reported in indi-
vidual articles; and (5) recommending whether there is
sufficient evidence to evaluate the impact of intake of the
flavan-3-ol content on cardiovascular health in a system-
atic review. An evidence map using pre-specified eligibility
criteria is a robust and effective method to determine
whether there is sufficient evidence on clinical outcomes,
intermediate outcomes, or dose-response data to allow a
formal re-examination of a particular broad topic.
The results of this evidence map suggest that there are suf-
ficient data available to conduct a systematic review and
meta-analysis of flavan-3-ol intake and CVD outcomes.
Moreover, additional studies may have been completed since
our last search date (April 2016). Most of the included RCTs
reported the presence or absence of blinding and had few
dropouts (enrolled vs. analyzed). Additionally, the body of
evidence from RCTs and cohort studies examining
flavan-3-ol interventions included a sufficient number of out-
comes of interest to justify a future systematic review and
meta-analyses. There will be challenges comparing different
flavan-3-ol sources in a systematic review or meta-analysis as
they will likely differ considerably in composition, bioaccessi-
bility, and in the presence of other bioactive compounds.
Flavan-3-ols from different sources may also vary in relation
to both bioavailability and bioactivity. Nonetheless, the evi-
dence from a full systematic review would bring credible
weight to deliberations about the relative importance of
flavan-3-ols per se (irrespective of source); may help guide
authoritative bodies, such as the Institute of Medicine (IOM)
on recommended intakes; and may assist the Dietary Guide-
lines Advisory Committee for 2020 guidelines. Currently, we
are embarking on a full systematic review on this topic, and
the literature search will be updated for additional studies
published since our last search date.
Conclusion
Our evidence mapping on flavan-3-ol intake and CVD uses
a systematic, evidence-based approach to search for, identify,
collect data on, and evaluate relevant studies examining the
effects of foods, beverages, and supplements/extracts high in
flavan-3-ols. This study on flavan-3-ol intake and CVD out-
comes demonstrated that there is sufficient data relating to
flavan-3-ol intake and biomarkers and clinical outcomes of
CVD and diabetes to potentially conduct a systematic re-
view and meta-analysis. It also highlighted as an evidence
gap a lack of long-term RCTs. Additional gaps in evidence
included fewer trials evaluating fruits such as apple, plums,
and grapes; fewer trials conducted among healthy adults
compared to at-risk populations; and except for green tea
and cinnamon, fewer trials from regions other than Western
Europe. The current evidence base highlights the distribu-
tion of available data that support the development of a
future systematic review and meta-analysis. Additionally, the
identification of evidence gaps can help prioritize and iden-
tify the key future research needs.
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